Claims for Patent: 6,251,666

Summary for Patent: 6,251,666

Title:	Nucleic acid catalysts comprising L-nucleotide analogs
Abstract:	A nucleic acid catalyst comprising at least one L-nucleotide substitution.
Inventor(s):	Beigelman; Leonid (Longmont, CO)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	09/048,825
Patent Claims:	1. A ribozyme comprising at least one L-nucleotide substitution. 2. The ribozyme of claim 1, wherein said L-nucleotide has the formula I: ##STR2## wherein, X is a nucleic acid base, which may be modified or unmodified, or H; Y is a phosphorus-containing group; R.sub.1 is H, OH or other 2'-modifications; and R.sub.2 is a blocking group or a phosphorus-containing group. 3. The ribozymne of claim 1, wherein said ribozyme has an endonuclease activity. 4. The ribozyme of claim 1, wherein said ribozyme is capable of cleaving a peptide linkage. 5. The ribozyme of claim 2, wherein said ribozyme cleaves a separate nucleic acid molecule. 6. The ribozyme of claim 1, wherein said ribozyme ligates separate nucleic acid molecules. 7. The ribozyme of claim 5, wherein said separate nucleic acid molecule is a ribonucleic acid molecule. 8. The ribozyme of claim 1, wherein said ribozyme consists of L-nucleotides at every position in the ribozyme. 9. The ribozyme of claim 3, wherein said ribozyme is in a hammerhead ribozyme motif. 10. The ribozyme of claim 3, wherein said ribozyme is in a hairpin ribozyme motif. 11. The ribozyme of claim 3, wherein said ribozyme is in a hepatitis delta virus, group I intron, group II intron, VS RNA or RNase P RNA motif. 12. The ribozyme of claim 1, wherein said ribozyme comprises at least two said L-nucleotide substitutions which may be same or different. 13. The ribozyme of claim 1, wherein said ribozyme comprises at least one D-nucleotide residue. 14. The ribozyme of claim 5, wherein said ribozyme comprises between 12 and 100 bases complementary to said separate nucleic acid molecule. 15. The ribozyme of claim 5, wherein said ribozyme comprises between 14 and 24 bases complementary to said separate nucleic acid molecule. 16. The ribozyme of claim 2, wherein said R.sub.1 is OH. 17. The ribozyme of claim 2, wherein said R.sub.1 is amino. 18. The ribozyme of claim 2, wherein said R.sub.1 is alkoxy. 19. The ribozyme of claim 2, wherein said X is selected from the group consisting of adenine, guanine, uracil, and cytosine. 20. A mammalian cell comprising the ribozyme of claim 1. 21. The mammalian cell of claim 20, wherein said mammalian cell is a human cell. 22. A pharmaceutical composition comprising the ribozyme of claim 1. 23. A method for modulating expression of a gene in a mammalian cell by administering to said cell at least one ribozyme of claim 1. 24. A method of cleaving a separate nucleic acid molecule comprising, contacting the ribozyme of claim 1 with said separate nucleic acid molecule under conditions suitable for the cleavage. 25. The method of claim 24, wherein said cleavage is carried out in the presence of a divalent cation. 26. The method of claim 25, wherein said divalent cation is Mg.sup.2+. 27. The ribozyme of claim 1, wherein said ribozyme is chemically synthesized. 28. The ribozyme of claim 9, wherein said L-nucleotide substitution is at positions 4, or 7 of said hammerhead ribozyme motif. 29. The ribozyme of claim 9, wherein said L-nucleotide substitution is at positions 4 and 7 of said hammerhead ribozyme motif. 30. The ribozyme of claim 9, wherein said L-nucleotide substitution is at the 3' terminal position of said hammerhead ribozyme motif.

Details for Patent 6,251,666

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-03-31
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-03-31
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-03-31